This article reviews the literature on the application of methods for the detection of growth factors, oncogene proteins, and tumor-suppressor gene proteins in the blood of humans with cancer or who are at risk for the development of cancer. The research summarized here suggests that many of these biomarker assays can be used to distinguish between diseased and nondiseased states and in some instances may be able to predict susceptibility for future disease. Thus, these biomarkers could be valuable tools for monitoring at-risk populations for purposes of disease prevention and control. -Environ Health Perspect 105(Suppl 4): 807-816 (1997) 
Introduction
The development of many cancers and some other environmentally related diseases is believed to be associated with the aberrant expression of genes that encode proteins involved in cellular growth signal transduction, including growth factors and the protein products of oncogenes and tumor-suppressor genes. This aberrant expression can involve a quantitative difference from normal (i.e., overexpression of the wild-type protein) and/or a qualitative difference (i.e., expression of a mutant form of the protein). The detection of increased expression of these proteins or expression of mutant forms of these proteins therefore represents a category of potential biomarkers with which to study This Numerous studies have documented this aberrant expression of growth factors and oncoproteins in diseased tissue compared to normal tissue. However, the techniques are somewhat complicated, and, in most cases, it would be difficult to obtain tissue samples for routine screening of atrisk populations. Fortunately, in many instances it is apparent that these proteins gain access to the extracellular environment and are thus detectable in easily obtainable biological fluids such as serum or plasma by techniques that are relatively simple, convenient, and easily standardized. Thus, this review will focus on the assay of growth factors and oncoproteins in extracellular fluids, particularly serum and plasma, by techniques that could readily be applied to study at-risk populations in developing as well as developed countries.
Growth Factors
Since growth factors are normally actively secreted from cells, they represent logical targets for detection in blood during disease development. Several studies have demonstrated differences in blood levels of growth factors between cancer patients and controls.
Platelet-derived Growth Factor
Platelet-derived growth factor (PDGF) , which functions as a dimer of A and B chains (PDGF-B is encoded by the sis oncogene), has been examined in the blood of various cancer patients. Plasma PDGF-B chain levels were determined by enzymelinked immunosorbent assay (ELISA) in 131 patients with cancers of various types (including carcinomas, sarcomas, and lymphomas) and 72 noncancer controls (1) . Levels were greater than the highest control value of 0.69 ng/ml in 19 (15%) of the cases, although, based on other markers, in only 5 (4%) of the cases was the tumor felt to be the source of the growth factor. Plasma PDGF levels have also been determined by radioimmunoassay (RIA) in 58 breast cancer patients and 9 normal female controls (2) . All of the controls were below the lower limit of detection of the assay (1.56 fmol/100 1l), but 20 of 17 (12%) stage II cancer patients had detectable levels and 13 of 41 (32%) stage IV cancer patients had elevated levels (defined as more than twice the lower limit of detection of the assay). Patients with elevated PDGF had a significantly greater degree of metastatic involvement and a significantly shorter survival time. Elevated levels of PDGF-related proteins have also been detected by immunoblotting in the urine of cancer patients (3).
Transforming Growth Factor (x Transforming growth factor cc (TGFa) is a 50-amino acid, single-chain polypeptide growth factor, and its proliferative effect is mediated through the epidermal growth factor receptor. TGFx, as determined by ELISA in plasma, was initially reported to be elevated in 71 patients with solid tumors (mean ± SD = 346 ± 155 pg/ml) compared to 66 controls (mean ± SD = 187 ± 29 pg/ml); but the differences were not statistically significant (4) . In another study, TGFca levels in pooled plasma samples determined by ELISA were 0.051 ng/ml in cancer patients (stomach, colon, liver) compared to 0.028 ng/ml in 15 healthy volunteers (5) . TGFx levels have also been measured by RIA in the serum of 83 breast cancer patients and 74 healthy controls (6) . Among the controls, 24 had nondetectable serum TGFa (< 100 pg/mr) and 50 (67%) had detectable levels that ranged from 120 to 207 pg/ml (mean±SD= 147± 18 pg/ml). All of the cancer cases had detectable serum TGFa levels that ranged from 210 to 740 pg/ml (mean ± SD = 353 ± 98 pg/ml), and the difference in the means between cases and controls was statistically significant (p< 0.00 1). The same RIA was also used to compare these control levels to serum TGFa in 100 patients with gastrointestinal cancers (esophageal, gastric, pancreatic, colonic, rectal) which ranged from 119 to 760 pg/ml (mean ± SD = 269 ± 102 pg/ml) (7) . Once again, the difference in the means between cases and controls was statistically significant ( (13) . Control values ranged from 2 to 12 ng/ml (mean ± SD = 4.1 ± 2.0 ng/ml), and 2 of the cancer patients (7%) were found to have elevated levels (defined as more than 2 SD above the control mean).
TGF02 was detectable in 2 of the cancer patients also, but not in any of the controls.
Basic Fibroblast Growth Factor
Basic fibroblast growth factor (bFGF) is a single-chain polypeptide composed of 146 amino acids. Basic fibroblast growth factor was initially reported to be detectable by ELISA in the serum of renal cell carcinoma patients (14) . Follow (18) . Furthermore, in all patients undergoing surgical resection, serum levels were statistically significantly lower after surgery than before, suggesting that the tumors were the source of the increased bFGF in serum in those cases. Levels of bFGF have also been reported to be elevated in the serum in other breast cancer patients (19) , in the plasma of patients with multiple endocrine neoplasia type I (20) and of patients with B-cell chronic lymphocytic leukemia (21) , and in the serum of patients with cervical cancer (22) . In the latter study, four of the 20 patients relapsed after complete remission and two of these had a continuous increase in serum bFGF levels before the clinical detection of relapse with a mean lead time of 4 months, suggesting that serum bFGF may be useful for the early detection of recurrences and possibly primary tumors.
Other
Plasma or serum levels of several other growth factors have been reported in various cancers. Epidermal growth factor (EGF) is elevated in the serum of some patients with stomach cancer (23), cancer of the tongue (24) , and ovarian cancer (25) , but unchanged or decreased in other cancers (26) (27) (28) . Insulinlike growth factors, (IGF) have been reported to be elevated in the plasma of some breast cancer patients (29) and ovarian cancer patients (25) , but not in other cancers (30, 31) . Elevated serum levels of hepatocyte growth factor (HGF) have been reported in hepatocellular carcinoma as well as in nonmalignant liver diseases (32) . In addition, many types of growth factors have been identified in other biological fluids, including urine (33) , effusions (34), cyst aspirates (35, 36) , and bronchoalveolar lavage (37 of the study (40) . Finally, in atherogenesis, high levels of total growth factor activity in plasma, 20% of which is attributable to PDGF, has been found to be significantly correlated with progression (r= 0.42, p< 0.05) and severity (r= 0.52, p< 0.01) of coronary atherosclerosis with elevated PDGF levels specifically correlated with the number and severity of stenoses (r= 0.40, p< 0.05) (41) .
Oncoproteins Growth Factor Receptors
Transmembrane growth factor receptors are frequently overexpressed in human malignancies. Overexpression is accompanied in many instances by cleavage of the extracellular domain (ECD) of the receptor with its accumulation in the extracellular environment. Thus, detection of increased amounts of the ECD of these receptors in blood is a potential biomarker of cancer development.
Many studies have examined the ECD of the p185 transmembrane growth factor receptor (encoded by the c-erbB-2 oncogene) in the blood of cancer patients. An initial study reported elevated serum erbB-2 ECD levels by ELISA (40-to 190-fold higher than controls) in 3 of 12 (25%) breast cancer patients compared to 35 controls (42) . Two of the cases with serum elevation also had increased tissue expression, suggesting that the tumors were the source of the serum proteins. Another study reported elevated serum erbB-2 ECD by ELISA (defined as greater than 2 (51, 52) . In addition, in this study, there were 7 cases of in situ carcinoma without invasion, and 3 of these (43%) had elevated serum ECD levels, suggesting that this may be a biomarker of early malignant disease in certain cases of breast cancer. Many additional studies on elevated serum erbB-2 ECD in breast cancer have been reported (53) (54) (55) (56) (57) (58) (59) . In the most recent study, elevated serum erbB-2 ECD was found in 3 of 66 (5%) controls, 0 of 12 (0%) cases of benign breast disease, 1 (64) (65) (66) . In another study, levels in the plasma of colonic adenoma patients were statistically significantly elevated compared to controls; patients with large adenomas had higher levels than patients with small adenomas (67) . In addition, the average serum erbB-2 ECD level in male Taiwanese who subsequently developed hepatocellular carcinoma was statistically significantly elevated compared to matched controls who did not develop cancer, and increasing levels showed a significant linear trend in relation to the subsequent development of cancer, with those individuals with elevated levels averaging over 2 years between the time of serum collection and the diagnosis of disease (68, 69) . These results support the hypothesis that serum erbB-2 ECD may be a biomarker of early malignant disease in some cases. Elevated serum erbB-2 ECD levels have also been described in patients with lung cancer (70) . In another study, levels measured in multiple banked serum samples from 11 pneumoconiosis patients who subsequently developed lung cancer were found to be statistically significantly elevated compared to controls, and in 4 of the cases, levels were elevated prior to the diagnosis of disease with a lead time averaging 35 months (71). This similarly supports the potential utility of this biomarker for the early diagnosis of malignant disease.
Recently, the ECD of the epidermal growth factor receptor (EGFR, encoded by the c-erbB-1 oncogene) has also been identified in cancer patients. The EGFR ECD was quantitated by ELISA in the banked serum samples from 38 asbestosis cases who subsequently developed cancer, 72 asbestosis controls without cancer matched for age, sex, race, smoking, and asbestos exposure, and 20 nonasbestosis, noncancer controls matched for age, sex, race, and smoking (72, 73) . The mean serum level for the EGFR ECD in the cancer cases (mean ± SD = 636 ± 299 fm/ml) was statistically significantly elevated (p< 0.05) in comparison to the mean level in the asbestosis controls (mean ± SD = 546 ± 147 fm/ml or the nonasbestosis controls (336 ± 228 fm/ml). Seven (76, 77) . In another study, increased serum p21 by ELISA was found in 3 of 13 (23%) patients with stomach cancer compared to 0 of 3 (0%) normal controls, although no increases were noted in 29 other patients with different cancers (78) . Elevated serum p2l has also been identified in individuals at risk for the development of cancer due to workplace carcinogen exposures (79) (80) (81) . In one of these cases, an individual with elevated serum p21 by immunoblotting 18 months later developed a premalignant colonic lesion, and once the lesion was removed the individual's serum p21 returned to normal (82) . This suggests that the tumor was the source for the elevated protein in serum and that this biomarker may be detectable prior to the identification of clinical disease. Elevated serum p21 has also been identified in lung cancer patients (83, 84 for the occurrence of the serum mutant p21 with increasing duration of exposure, and, since increased exposure is associated with increased cancer risk, this suggests that serum mutant p21 may be a biomarker of early carcinogenic change in some cases.
Other biomarkers of ras gene mutation have also been identified in blood. For example, the identification of mutant ras genes by polymerase chain reaction and direct sequencing of DNA isolated from the serum or plasma of three patients with pancreatic cancer has been described (89 (96) . Antibodies to the myc protein have also been described in the sera of patients with myeloid leukemia and lymphoma, including Burkitt's lymphoma (97) . Serum antibodies to other oncogene proteins have also been identified in cancer patients (98) . Tumor Suppressor Gene Proteins The most frequent site for mutations in human cancers is the tumor suppressor gene encoding p53, a 53-kDa nuclear phosphoprotein. The effect of these mutations is to cause loss of the normal growth inhibitory function of p53 with a concomitant accumulation of the mutant proteins in the transformed cells due to the considerably increased half-lives of mutant p53s. Accumulations of mutant p53 have been frequently identified by immunohistochemistry in human tumors and in some cases lead to accumulations in the extracellular environment resulting in potential biomarkers in the blood.
Increased levels of mutant p53 in serum determined by ELISA (greater than 0.3 ng/ml, the upper limit of 100 normals) was first reported in 11 of 54 (20%) patients with hepatocellular carcinoma as well as 30% of patients with cirrhosis, a group known to be at increased risk for the development of hepatocellular carcinoma (99) . Elevated serum mutant p53 levels determined by ELISA have also been reported in 5 of 60 (8%) breast cancer patients, with levels decreasing following surgical resection of the tumors, although tissue immunochemistry for p53 correlated poorly with serum levels (100). In another study, elevated serum mutant p53 by ELISA was found in 15 of 82 (18%) breast cancer patients compared to 0 of 20 (0%) normals (101) . Elevated serum mutant p53 levels determined by ELISA and immunoblotting were also found in 3 of 23 (13%) lung cancer patients compared to 0 of 23 (0%) controls matched for age, sex, and race and 2 of 58 (3%) unmatched controls, and increased tissue p53 and/or the presence of p53 gene mutations were found in the 3 serum-positive cancer cases (102) . In a larger study of lung cancer patients, elevated levels of mutant p53 were detected by ELISA in the serum of 17 of 50 (34%) non-small cell lung cancer patients compared to 0 qf 15 (0%) controls, and the levels of p53 protein accumulation in the tumor tissue by immunohistochemistry were found to be strongly correlated with the levels of p53 in the serum (p= 0.007) (103) . Elevated levels of mutant p53 have also been reported in the plasma of 21 of 65 (32%) patients with non-Hodgkin's lymphoma (104) and in the serum of 6 of 33 (18%) patients with Hodgkin's lymphoma (105) . In another study, elevated total serum p53 protein (greater than 10 controls) was reported in 6 of 16 (38%) patients with colonic adenomas and 18 of 28 (64%) patients with colonic carcinomas (106) . In another study of colonic neoplasms, plasma levels of mutant p53 were found to be statistically significantly elevated among 54 cases of colonic adenomas (mean = 0.44 ng/ml) and 22 cases of colonic carcinomas (mean = 0.55 ng/ml) compared to 47 individuals with negative colonoscopic examinations (mean=0.12 ng/ml) (p< 0.02), and plasma levels tended to increase with increasing adenoma size and increasing carcinoma stage (107) . Total serum p53 levels have also been found to be statistically significantly elevated among 22 former uranium miners with lung cancer compared to 7 healthy controls (p= 0.003) (74) . In a study of banked serum samples from asbestosis patients, elevated total and mutant serum p53 was found in up to 6 of 32 (19%) patients who subsequently developed cancer compared to 2 of 36 (6%) asbestosis patients without cancer and 1 of 10 (10%) nonasbestosis controls; in 1 serum-positive case of lung cancer, elevated p53 levels were found in the tumor tissue, and in several of the cases elevated levels were present in serum years prior to the dinical diagnosis of disease (8, 108) . Serum mutant p53 has also been examined in vinyl chloride-exposed workers with and without angiosarcomas of the liver. Two cases of ASL known to contain p53 gene mutations were found to have elevated serum mutant p53 by ELISA compared to 2 cases of ASL and the one case of hepatocellular carcinoma known not to contain p53 gene mutations. In addition, 3 of 19 (16%) VC-exposed workers without liver lesions were also serum-positive for mutant p53 compared to 0 of 5 (0%) matched unexposed controls (109 (115) . p53 antibodies were reported in the serum in 9 of 175 (5%) patients with various cancers (including colon, breast, lung, and ovary) compared to 0 of 22 (0%) controls (116 (121) . In a large recent study of p53 antibodies in serum in 1392 patients with various malignancies determined by two methods, the highest prevalence of antibodies was found in ovarian and colon cancers (15%), lung cancers (8%) and breast cancers (5%) with lower prevalences in other malignancies (<4%) and controls (< 1-2%) (122) . In a study of vinyl chloride-exposed workers, 9 patients with ASLs were found to have p53 antibodies in their serum, and in 3 cases these were detectable prior to the clinical detection of disease (average= 8 years), once again supporting the hypothesis that this may be an early biomarker of disease in certain cases (123 
